Abstract:OBJECTIVE:To measure the urokinase-type plasminogen activator (UPA) and its receptor (UPAR) in the plasma of patients with cerebral infarction and to study the effects of UPA and UPAR on cerebral infarction.METHODS:ELISA sandwich method was used to measure the plasma levels of UPA and UPAR in 89 patients with acute cerebral infarction, subdivided into mild, moderate and severe subgroups according to the modified Edinburgh-Scandinavia stroke scale (mESSS), and 30 patients with other disease and 30 healthy persons as controls.RESULTS:Within 2 days after the onset of cerebral infarction the UPA and UPAR levels were (1663.7 +/- 384.2) ng/L and (1 375.3 +/- 303.0) ng/L respectively, both significantly higher than those of the patients with other diseases [(1 033.0 +/- 122.7) ng/L and (978.3 +/- 120.0) ng/L respectively (P = 0.038 and P = 0.000)] and those of the normal control group [(1 005.0 +/- 128.9) ng/L and (904.7 +/- 158.6) ng/L respectively, both P = 0.000]. Two weeks after the onset of stroke, the plasma UPA level was (1 185.5 +/- 384.6) ng/L, not significantly different from those of the 2 control groups (both P > 0.05); while the plasma UPAR level in the cerebral infarction was (1 159.3 +/- 261.2) ng/L, significantly higher than those in the 2 control groups (P < 0.01). Within 2 days after the onset of infarction the plasma UPA and UPAR levels of the severe subgroup were (1 938.9 +/- 256.5) ng/L and (1 510.8 +/- 378.7) ng/L respectively, both significantly higher than those of the moderate subgroup [(1 593.7 +/- 204.8) ng/L and (1 296.6 +/- 151.2) ng/L respectively, both P < 0.01] and those of the mild subgroup [1 358.5 +/- 175.9] ng/L and (1 226.8 +/- 98.3) ng/L respectively, both P < 0.01], Two weeks after the onset of stroke,the plasma UPA and uPAR levels of the severe subgroup remained significantly higher than those of the mild subgroup [(1 152.6 +/- 170.3) ng/L vs (1 041.9 +/- 187.0) ng/L, (P < 0.05)] and [(1 186.4 +/- 158.3) ng/L vs (1 053.9 +/- 109.4) ng/L, (P < 0.01)]. In addition, the plasma UPA and UPAR levels of the patients who died from cerebral infarction at last were the highest among all the groups.CONCLUSION:The plasma levels pf UPA and UPAR increase in patients with cerebral infarction and may be related with the severity of disease. The UPA and UPAR genes may play an important role via proteolytic degradation of the extracellular matrix and basement membrane during the development of cerebral infarction.

Clinical Significance of Platelet-Leukocyte Aggregates in Patients with Acute Cerebral Infarction

Changes of platelet-leukocyte aggregations in patients with acute cerebral infarction

The Effects of Antiplatelet Agents on Platelet–leukocyte Aggregations in Patients with Acute Cerebral Infarction

Study on Platelet Activation and Platelet Parameters in Patients with Cerebral Infarction

Clinical Significance of PAC-1, CD62P, and Platelet-Leukocyte Aggregates in Acute Ischemic Stroke

Analysis of correlation between oxidized low density lipoprotein and thrombus precursor protein with acute cerebral infarction

Study on the Changes of Plasma Levels of Brain natriureticpeptide(BNP) and C-Reactive Protein(CRP) in Patients with Acute Cerebral Infarction

Study on the Changes of Serum Levels of Interleukin-1β(IL-1β) and C-Reactive Protein(CRP) in Patients with Acute Cerebral Infarction

Clinical Analysis of Platelet Parameters in Patients with Acute Cerebral Infarction

Study on expression of platelet membrane glycoproteins in cerebral infarction with carotid atherosclerosis

The Research about the State of the Activated Blood Platelet of Cerebral Infarction Patients

The Relativive Studies Between the Concentration of GMP-140 in Plasma and Platelet Aggregation in Patients with Acute Cerebral Infarction

Differences in platelet–leukocyte aggregates among subtypes of acute cerebral ischemia

Changes of Platelet Activation Markers and Platelet Ultra-Microstructure in the Patients with Acute Myocardial Infarction

Elevated Levels of Platelet-Monocyte Aggregates and Related Circulating Biomarkers in Patients with Acute Coronary Syndrome.

[Expression of Urokinase-Type Plasminogen Activator and Its Receptor in Plasma of Patients with Cerebral Infarction].

Role of platelet activating factor in diagnosis and treatment of acute cerebral infarction

Evaluation of lipoprotein‐associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction

Investigation of the relation between platelet activation and ischemic stroke disease

The Changes and Clinical Significance of the Platelet Parameters in Patients with Ischemic Stroke

Platelet Ultrastructural and Functional Studies in Patients with Acute Cerebral Infarction